Updated COVID-19 Vaccine Has Effectiveness of 54 Percent
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 6, 2024 -- Updated monovalent COVID-19 vaccines offer vaccine effectiveness (VE) of 54 percent against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to research published in the Feb. 1 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Ruth Link-Gelles, Ph.D., from the CDC in Atlanta, and colleagues analyzed data from the Increasing Community Access to Testing SARS-CoV-2 pharmacy testing program to estimate updated 2023 to 2024 COVID-19 VE against symptomatic SARS-CoV-2 infection with a monovalent XBB.1.5-derived vaccine.
The researchers found that overall VE among adults aged 18 years and older was 54 percent at a median of 52 days after vaccination among 9,222 total eligible tests. VE at 60 to 119 days after vaccination was 49 percent among tests exhibiting spike gene target failure (SGTF) and 60 percent among tests without SGTF in a total of 2,199 tests performed at a laboratory with SGTF testing.
"Vaccination provided protection for infections caused by JN.1 and infections caused by XBB-related lineages. Waning of effectiveness is expected with additional elapsed time since vaccination, especially against less severe disease," the authors write. "All persons aged ≥6 months should stay up to date with COVID-19 vaccination, including receiving a dose of updated vaccine."
One author disclosed ties to Eagle Health Analytics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-02-07 22:15
Read more
- Cataract Surgery Could Save Your Eyesight and Maybe Your Life
- Hourglass-Shaped Stent Might Ease Tough-to-Treat Angina
- Oct. 7 Tragedy Spurs Israeli Researcher to Study Grief Over Sibling Loss
- Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
- Postpartum Exercise Cuts Odds of Postpartum Depression
- U.S. Alcohol Intake Rose During Pandemic, and for Years After
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions